Literature DB >> 15999234

Psychotic symptoms in Parkinson's disease. From description to etiology.

Spiridon Papapetropoulos1, D C Mash.   

Abstract

Psychotic symptoms are common in Parkinson's disease (PD) and occur in at least 20% of medication-treated patients. Benign visual hallucinations usually appear earlier, while malignant hallucinations, confusional states, delusions, paranoid beliefs, agitation, and delirium become more frequent with disease progression. Virtually all antiparkinsonian drugs may produce psychotic symptoms. Cognitive impairment, increased age, disease duration and severity, depression, and sleep disorders have been consistently identified as independent risk factors for their development. Although the precise pathoetiologic mechanisms remain unknown, we review evidence that links ventral dopaminergic pathway dysfunction (overactivity) together with the involvement of other neurotransmitter system imbalances as likely contributors. The clinical importance of the proposed mechanism is that successful management of psychotic symptoms in PD may rely on a multitarget approach to restore neurotransmitter imbalances rather than focusing exclusively on the dopaminergic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15999234     DOI: 10.1007/s00415-005-0918-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  102 in total

1.  Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.

Authors:  M A Piggott; E F Marshall; N Thomas; S Lloyd; J A Court; E Jaros; D Burn; M Johnson; R H Perry; I G McKeith; C Ballard; E K Perry
Journal:  Brain       Date:  1999-08       Impact factor: 13.501

2.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease.

Authors:  C W Olanow; T Freeman; J Kordower
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

3.  Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis.

Authors:  I Arnulf; A M Bonnet; P Damier; B P Bejjani; D Seilhean; J P Derenne; Y Agid
Journal:  Neurology       Date:  2000-07-25       Impact factor: 9.910

4.  Psychosis in Dementia With Lewy Bodies.

Authors: 
Journal:  Semin Clin Neuropsychiatry       Date:  1998-01

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

Authors:  W H Poewe; G Deuschl; A Gordin; E-R Kultalahti; M Leinonen
Journal:  Acta Neurol Scand       Date:  2002-04       Impact factor: 3.209

7.  Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.

Authors:  J D Parkes; R C Baxter; C D Marsden; J E Rees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-04       Impact factor: 10.154

8.  Mortality and hallucinations in nursing home patients with advanced Parkinson's disease.

Authors:  C G Goetz; G T Stebbins
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

9.  Donepezil in the treatment of hallucinations and delusions in Parkinson's disease.

Authors:  G Fabbrini; P Barbanti; C Aurilia; C Pauletti; G L Lenzi; G Meco
Journal:  Neurol Sci       Date:  2002-04       Impact factor: 3.307

10.  Pharmacology of hallucinations induced by long-term drug therapy.

Authors:  C G Goetz; C M Tanner; H L Klawans
Journal:  Am J Psychiatry       Date:  1982-04       Impact factor: 18.112

View more
  30 in total

Review 1.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

Review 2.  Recognition and management of neuropsychiatric complications in Parkinson's disease.

Authors:  Florian Ferreri; Catherine Agbokou; Serge Gauthier
Journal:  CMAJ       Date:  2006-12-05       Impact factor: 8.262

Review 3.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

Review 4.  Non-motor features of Parkinson disease.

Authors:  Anthony H V Schapira; K Ray Chaudhuri; Peter Jenner
Journal:  Nat Rev Neurosci       Date:  2017-06-08       Impact factor: 34.870

Review 5.  Agitation and psychosis associated with dementia with lewy bodies exacerbated by modafinil use.

Authors:  Eduardo Prado; Pongsatorn Paholpak; Myha Ngo; Verna Porter; Liana G Apostolova; Rogério Marrocos; John M Ringman
Journal:  Am J Alzheimers Dis Other Demen       Date:  2012-08-14       Impact factor: 2.035

6.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

Review 7.  Parkinson disease: an update.

Authors:  Steven J Frucht
Journal:  Neurologist       Date:  2004-07       Impact factor: 1.398

8.  Neuroticism and extraversion in association with quality of life in patients with Parkinson's disease.

Authors:  Tatiana Dubayova; Iveta Nagyova; Eva Havlikova; Jaroslav Rosenberger; Zuzana Gdovinova; Berrie Middel; Jitse P van Dijk; Johan W Groothoff
Journal:  Qual Life Res       Date:  2008-11-07       Impact factor: 4.147

9.  Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.

Authors:  Daniel Ecker; Alexander Unrath; Jan Kassubek; Michael Sabolek
Journal:  BMC Neurol       Date:  2009-06-10       Impact factor: 2.474

10.  Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphisms.

Authors:  David A Ziegler; Paymon Ashourian; Julien S Wonderlick; Alison K Sarokhan; Drazen Prelec; Clemens R Scherzer; Suzanne Corkin
Journal:  Scand J Psychol       Date:  2014-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.